Warnex Medical Laboratories offers a range of specialized and sophisticated biochemical analyses, complementing routine tests. We have extensive expertise in prenatal testing and offer the earliest and most effective Down syndrome screening test available.
The Prenatest® prenatal screening test is designed to inform the expecting mother of the risk that her foetus is affected by Down syndrome (trisomy 21), trisomy 18 and other chromosomal abnormalities (ex. Trisomy 13). The Prenatest method combines a simple blood test with the ultrasound measurements of the foetus' nuchal translucency with or without nasal bone. It is the earliest and most effective Down syndrome screening test available in the first trimester.
For more information, visit www.prenatest.ca
The bioavailable testosterone test is a diagnostic test recommended for male patients in evaluating a condition known as andropause. Andropause is caused by a decrease in hormone with age, which plays a direct role in various physiological changes, including muscle strength, bone density and body composition. Warnex's test measures the amount of bioavailable testosterone, the biologically active form of testosterone, in human serum.
PCA3 Test for Prostate Cancer
Warnex's PCA3 test for the detection of prostate cancer is highly specific and more precise than all other available screening tests for prostate cancer. The PCA3 test is a molecular biology assay that measures the expression of PCA3 mRNA in urine samples. PCA3 is specific to the prostate and is significantly up-regulated (60-100 fold) in prostatic cancerous cells. The test quantitatively measures PCA3 mRNA as well as PSA mRNA and determines their ratio. High ratios have been shown to be indicative of prostate cancer. PCA3 screening may help reduce the number of unnecessary biopsies. In addition, the test is non-invasive, eliminating pain and discomfort associated with biopsies. Warnex is the first laboratory to offer this service in Canada.
For more information, visit www.pca3.ca
Gleevec® Monitoring Service
Gleevec® (imatinib mesylate) is a drug approved for the treatment of patients suffering from chronic myeloid leukemia (CML) or gastro-intestinal stromal tumours. It is a small molecule that inhibits the ATP binding site of the ABL tyrosine kinase function. Warnex's Gleevec® monitoring service provides practicing physicians with clinically relevant information to help monitor and optimize patient treatment. Physicians may monitor their patients for the following reasons:
- To obtain a base line level
- Lack of response or sub-optimal response
- Loss of response
- Severe side effect for dose taken
- Suspected drug-drug interaction
Warnex measures Gleevec® blood levels using state-of-the-art high performance liquid chromatography coupled with mass spectrometry (LC/MS/MS), a highly specific and sensitive method for performing bioanalysis.